Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00949325 · OUTCOME

Mean Progression Free Survival of Subjects Who Were Treated at the Temsirolimus MTD, 20 mg/m^2

Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma · Source last updated 2019-03-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
Days
Interval / dispersion
Full Range
Time frame
up to 3 years

What was measured

Interval from start of treatment to disease progression or death from any cause. Disease progression is defined as at least 20% increase in sum of longest diameter of target lesions or appearance of any new lesions. Subjective determination of significant worsening of disease-related symptoms was considered clinical disease progression

Groups in this outcome

Subjects Who Received Temsirolimus MTD, 20 mg/m^2

All subjects who received at least one dose of temsirolimus at the MTD, 20 mg/M\^2 plus liposomal doxorubicin were included.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Subjects Who Received Temsirolimus MTD, 20 mg/m^216

Reported measurements

Source class 1
Values in Days · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Subjects Who Received Temsirolimus MTD, 20 mg/m^2195Not reported7797Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        7
        upper Limit
        797
        value
        195
denoms
  1. counts
    1. group Id
      OG000
      value
      16
    units
    Participants
description
Interval from start of treatment to disease progression or death from any cause. Disease progression is defined as at least 20% increase in sum of longest diameter of target lesions or appearance of any new lesions. Subjective determination of significant worsening of disease-related symptoms was considered clinical disease progression
dispersion Type
Full Range
groups
  1. description
    All subjects who received at least one dose of temsirolimus at the MTD, 20 mg/M\^2 plus liposomal doxorubicin were included.
    id
    OG000
    title
    Subjects Who Received Temsirolimus MTD, 20 mg/m^2
param Type
MEAN
reporting Status
POSTED
time Frame
up to 3 years
title
Mean Progression Free Survival of Subjects Who Were Treated at the Temsirolimus MTD, 20 mg/m^2
type
SECONDARY
unit Of Measure
Days

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice